
Publication|Articles|June 2, 2025
- Vol 53 No 06
- Volume 53
- Issue 06
Survey: New NMIBC treatments face slow uptake
Fact checked by: Hannah Clarke
Listen
0:00 / 0:00
Key Takeaways
- The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices.
- Michael S. Cookson, MD, and Jason M. Hafron, MD, offer expert analysis of the survey data, enhancing understanding of the findings.
Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
Advertisement
How to engage with the survey:
- Open the survey by clicking the image or link above. It will open the interactive publication in a new browser window.
- Arrows on both sides of the screen allow you to navigate from page to page.
- There are buttons on the bottom-right of your screen to display thumbnails of all the pages beneath the viewer, or to zoom in/out, or make full screen.
- When you come across video content, you can click to watch within the publication.
- For now, the survey link performs better for desktop/laptop viewing. You can view on mobile but some interactive experiences may not be available.
- Questions? Problems? Feedback?
Please reach out to Assistant Managing Editor Ben Saylor.
What's in the survey:
- Developed by Urology Times Co–Editor in Chief Michael S. Cookson, MD, MMHC, FACS, the survey polled urologists regarding treatment patterns and preferences in non–muscle invasive bladder cancer.
- In the article accompanying the results, Cookson, along with Urology Times Clinical Practice Board member Jason M. Hafron, MD, provide insights on the survey data.
- Also included are exclusive interviews with Mary Beth Westerman, MD, and Rebecca A. Campbell, MD, who each provide expert commentary on the survey's contents.
Articles in this issue
about 1 year ago
En bloc resection of bladder tumor: Is it the way forward?about 1 year ago
Clarifying CPT 52353 billing for same-side stone casesabout 1 year ago
Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPCabout 1 year ago
Cretostimogene yields high CR rate in BCG-unresponsive NMIBCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
3
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
4
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
5













